Glenmede Trust CO Na Xencor Inc Transaction History

Glenmede Trust CO Na

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$36.63 - $47.63 $25,567 - $33,245	-698 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$30.09 - $43.02 $1,323 - $1,892	44 Added 6.73%	698 $26,000
Q2 2020 Aug 14, 2020	BUY	$27.76 - $33.42 $4,469 - $5,380	161 Added 32.66%	654 $20,000
Q4 2019 Feb 12, 2020	BUY	$32.75 - $41.43 $5,043 - $6,380	154 Added 45.43%	493 $16,000
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $11,434 - $15,685	339 New	339 $11,000
Q1 2019 May 14, 2019	SELL	$27.85 - $38.09 $17,963 - $24,568	-645 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$32.39 - $42.05 $53,281 - $69,172	-1,645 Reduced 71.83%	645 $23,000
Q3 2018 Nov 15, 2018	SELL	$35.69 - $47.65 $21,949 - $29,304	-615 Reduced 21.17%	2,290 $88,000
Q2 2018 Aug 15, 2018	BUY	$28.41 - $42.41 $82,531 - $123,201	2,905 New	2,905 $108,000

204

63.1M

3.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.21B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.